2025
Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers
Zakeri K, Wren S, Shang T, Yu Y, Chen L, Shamseddine A, Safavi A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers. Head & Neck 2025 PMID: 40515499, DOI: 10.1002/hed.28217.Peer-Reviewed Original ResearchP16-negative oropharyngeal cancerNodal recurrenceLocoregional recurrenceP16-negativeDistant recurrenceOropharyngeal cancerHead and neck cancer patientsRadiation doseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent chemoradiationRadiotherapy doseMedian followConsecutive patientsTreatment toxicityImprove quality of lifeConsecutive cohortCancer patientsRecurrenceQuality of lifeHypopharyngealDosePatientsOutcome measures
2024
Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers
Zakeri K, Shang T, Yu Y, Chen L, Shamseddine A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e807. DOI: 10.1016/j.ijrobp.2024.07.1772.Peer-Reviewed Original ResearchP16-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomasOropharyngeal squamous cell carcinomaDistant recurrenceSquamous cell carcinomaNodal recurrenceRadiotherapy doseLocoregional recurrenceP16 statusCell carcinomaHypopharynx cancerP16-negative oropharyngeal cancerHead and neck cancer patientsRadiation doseElective nodal volumesP16-negative diseaseNode-positive diseaseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent cetuximabConcurrent chemotherapyLocoregional controlMedian followNodal diseaseA Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients
Colevas A, Chung C, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Margossian S, Pai S. A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e87. DOI: 10.1016/j.ijrobp.2024.01.192.Peer-Reviewed Original ResearchCD8+ T cellsR/M HNSCCHuman leukocyte antigenT cellsHLA-A*0201Phase 1 dose-escalationTumor antigen-specific CD8First-in-human studyHead and neck cancer patientsTargeted delivery of cytokinesHLA-A*0201 patientsHPV16 E7 peptidesRecurrent/metastatic (R/MData cut-offInfusion-related reactionsT-cell engagersDelivery of cytokinesNeck cancer patientsTreatment of patientsPembrolizumab combinationDose escalationEscalating dosesComplete responseMaculopapular rashLeukocyte antigenLongitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study
Koutroumpakis E, Mohamed A, Chaftari P, Rosenthal D, Gujral D, Nutting C, Kamel S, Naser M, Kim P, Bassett R, Fuller C, Mouhayar E, Group A. Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study. Radiotherapy And Oncology 2024, 195: 110220. PMID: 38467343, PMCID: PMC11380547, DOI: 10.1016/j.radonc.2024.110220.Peer-Reviewed Original ResearchIntima-media thicknessGlobal circumferential strainRadiation therapyCarotid arteryHead and neck RTHead and neck cancer patientsHead and neck cancerNeck radiation therapyCircumferential strainNeck cancer patientsCarotid intima-media thicknessCarotid artery injuryArtery duplex studiesCarotid artery stenosisNeck RTNo significant differenceNeck cancerDuplex studiesArterial injuryArtery stenosisCancer patientsMedia thicknessCarotid ultrasoundArterial elastanceCarotid
2023
674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
Chung C, Adkins D, Dimitrios Colevas A, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Chaney M, Agensky L, Goel A, Quayle S, Margossian S, Levisetti M, Pai S. 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients. 2023, a764-a764. DOI: 10.1136/jitc-2023-sitc2023.0674.Peer-Reviewed Original Research
2020
Emergency Department Presentations Resulting in Percutaneous Endoscopic Gastrostomy Tube Placement Among Head and Neck Cancer Patients
Talcott W, Blakaj A, Jairam V, Park H. Emergency Department Presentations Resulting in Percutaneous Endoscopic Gastrostomy Tube Placement Among Head and Neck Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e838-e839. DOI: 10.1016/j.ijrobp.2020.07.378.Peer-Reviewed Original ResearchMolecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer
Drobin K, Marczyk M, Halle M, Danielsson D, Papiez A, Sangsuwan T, Bendes A, Hong MG, Qundos U, Harms-Ringdahl M, Wersäll P, Polanska J, Schwenk JM, Haghdoost S. Molecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer. Cancers 2020, 12: 753. PMID: 32235817, PMCID: PMC7140105, DOI: 10.3390/cancers12030753.Peer-Reviewed Original ResearchSingle nucleotide polymorphismsCancer patientsRadiosensitive patientsProteomic dataDNA repairSNP variantsRadiation-induced toxicityNeck cancer patientsLong-term survivalPredictors of radiosensitivityNucleotide polymorphismsProteinAdverse health effectsPlasma proteomicsGrowth capacityNeck cancerPredictive proteinsBreast cancerImmune responsePatient radiosensitivityPatientsStudy setDNA genotypingMolecular profilingNormal tissuesTemporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base
Kitpanit S, Lee A, Pitter KL, Fan D, Chow JCH, Neal B, Han Z, Fox P, Sine K, Mah D, Dunn LA, Sherman EJ, Michel L, Ganly I, Wong RJ, Boyle JO, Cohen MA, Singh B, Brennan CW, Gavrilovic IT, Hatzoglou V, O'Malley B, Zakeri K, Yu Y, Chen L, Gelblum DY, Kang JJ, McBride SM, Tsai CJ, Riaz N, Lee NY. Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. International Journal Of Particle Therapy 2020, 6: 17-28. PMID: 32582816, PMCID: PMC7302730, DOI: 10.14338/ijpt-20-00014.1.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiation-naïve patientsDose-volume parametersSkull baseNeck cancerTemporal lobeCutoff valueMaximum doseProton therapyAdverse Events v5.0Common Terminology CriteriaTemporal lobe necrosisNeck cancer patientsDose-volume factorsTerminology CriteriaMedian followBrain necrosisMedian timeClinical parametersCancer patientsMedical recordsGrade 3Necrosis rateField of radiationPatients
2019
Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy
Ng S, Pollard C, Kamal M, Ayoub Z, Garden A, Bahig H, Gunn G, Frank S, Skinner H, Phan J, Berends J, Morrison W, Johnson J, Ferrarotto R, Sturgis E, Mohamed A, Lai S, Fuller C, Rosenthal D. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology 2019, 3: 22. PMID: 31583278, PMCID: PMC6764977, DOI: 10.1038/s41698-019-0097-y.Peer-Reviewed Original ResearchSecond primary malignanciesDefinitive radiotherapyFormer smokersCurrent smokersOverall survivalPrimary malignancyRisk of SPMCurative-intent therapyIndex oropharyngeal cancersCompletion of radiotherapySignificant smoking historyKaplan-Meier methodMajority of patientsNeck cancer patientsSame risk factorsNeck cancer treatmentEligible patientsSPM ratesPack yearsSmoking historyOropharyngeal cancerInvasive cancerCancer patientsRisk factorsClinical dataClinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgression
2018
Cost of Surveillance Imaging in Head and Neck Cancer Patients Treated With Definitive Radiation therapy
Ng S, Kamal M, Pollard C, Berends J, Ayoub Z, Mohamed A, Gunn G, Frank S, Skinner H, Phan J, Morrison W, Rosenthal D, Garden A, Johnson J, Lai S, Sturgis E, Fuller C. Cost of Surveillance Imaging in Head and Neck Cancer Patients Treated With Definitive Radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 2018, 100: 1387-1388. DOI: 10.1016/j.ijrobp.2017.12.208.Peer-Reviewed Original ResearchSecond Primary Malignancies in Head and Neck Cancer Patients Treated With Definitive Radiation Therapy
Ng S, Kamal M, Pollard C, Berends J, Ayoub Z, Mohamed A, Gunn G, Frank S, Skinner H, Phan J, Morrison W, Garden A, Johnson J, Ferrarotto R, Lai S, Sturgis E, Fuller C, Rosenthal D. Second Primary Malignancies in Head and Neck Cancer Patients Treated With Definitive Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2018, 100: 1352. DOI: 10.1016/j.ijrobp.2017.12.119.Peer-Reviewed Original Research
2017
Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns
Gupta A, Sonis S, Schneider E, Villa A. Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns. Cancer 2017, 124: 760-768. PMID: 29112234, DOI: 10.1002/cncr.31095.Peer-Reviewed Original ResearchConceptsHNC patientsHospital typeUninsured patientsInsurance typeMortality riskInsurance-related disparitiesInferior survival outcomesNationwide Inpatient SampleNeck cancer patientsLogistic regression modelsOptimum treatment outcomesMultinomial logistic regression modelsPatient agePoor outcomeSurvival outcomesPrimary exposureCancer patientsInpatient SampleHNC outcomesInpatient careTreatment outcomesHospital settingProvider typePatientsGovernment hospitalsCost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy.
Ng S, Jomaa M, Pollard C, Ayoub Z, Mohamed A, Garden A, Berends J, Gunn G, Frank S, Skinner H, Phan J, Rosenthal D, Morrison W, Johnson J, Sturgis E, Lai S, Fuller C. Cost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy. Journal Of Clinical Oncology 2017, 35: 6610-6610. DOI: 10.1200/jco.2017.35.15_suppl.6610.Peer-Reviewed Original ResearchNeck cancer patientsSalvageable recurrenceAsymptomatic patientsDefinitive radiotherapyOverall survivalClinical findingsCancer patientsAdverse clinical findingsEarly salvage treatmentRecurrence-related deathsSuccessful salvage rateDisease-free intervalMedian overall survivalGroup of patientsChemotherapy useEligible patientsLR relapseSalvage therapyDistant relapseSalvage treatmentDisease recurrenceSalvage rateClinical outcomesMedian timeMean age
2016
Holistic Wellness Intervention for Head and Neck Cancer (HNC) Patients and Caregivers: Mayo Clinic Rochester (MCR) Pilot
Price K, Price D, Dierks L, Rhodes D, Ferguson J, Peterson S, Hein J, Murad A, Clark M, Olsen K. Holistic Wellness Intervention for Head and Neck Cancer (HNC) Patients and Caregivers: Mayo Clinic Rochester (MCR) Pilot. International Journal Of Radiation Oncology • Biology • Physics 2016, 94: 969-970. DOI: 10.1016/j.ijrobp.2015.12.345.Peer-Reviewed Original Research
2015
Refusal of postoperative radiotherapy and its association with survival in head and neck cancer
Schwam ZG, Husain Z, Judson BL. Refusal of postoperative radiotherapy and its association with survival in head and neck cancer. Radiotherapy And Oncology 2015, 117: 343-350. PMID: 26508285, DOI: 10.1016/j.radonc.2015.10.013.Peer-Reviewed Original ResearchConceptsNeck cancer patientsPostoperative radiotherapyPredictive factorsCancer patientsOverall survivalNegative nodesThree-year overall survivalCox proportional hazards analysisNational Cancer DatabaseProportional hazards analysisLong-term outcomesMultivariable logistic regressionSlow disease progressionCharlson scorePathologic variablesImproved survivalKaplan-MeierNeck cancerCancer DatabaseDisease progressionRetrospective analysisMultivariate analysisPatientsLogistic regressionSelect headNational treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database
Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyComorbidityDatabases, FactualFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPopulation SurveillanceRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesYoung AdultConceptsNational Cancer DatabaseSystemic therapyPalliative therapyTreatment patternsNeck cancerCancer DatabaseClinical trialsMedicaid/uninsured statusCox proportional hazards analysisCommon treatment regimenNational treatment patternsCharlson comorbidity scorePrimary disease siteRetrospective cohort analysisProportional hazards analysisRisk of deathNeck cancer patientsMedicare/Comorbidity scoreMetastatic headOverall survivalSystemic treatmentTreatment regimenDistant metastasisKaplan-MeierInflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.
Seiwert T, Burtness B, Weiss J, Eder J, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford J, Mehra R, Heath K, Cheng J, Chow L. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. Journal Of Clinical Oncology 2015, 33: 6017-6017. DOI: 10.1200/jco.2015.33.15_suppl.6017.Peer-Reviewed Original ResearchEvolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients
Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Research 2015, 75: 1205-1215. PMID: 25691460, PMCID: PMC4615655, DOI: 10.1158/0008-5472.can-14-2729.Peer-Reviewed Original ResearchConceptsNeck cancer patientsEvolutionary action scoreCancer patientsTP53 mutationsNeck squamous cell carcinomaSquamous cell carcinomaCisplatin-based therapyPlatinum-based therapySubset of headThird of casesNovel scoring systemSurvival benefitProspective evaluationCell carcinomaPlatinum responsePreclinical modelsTreatment selectionAction scoresScoring systemPatientsHNSCCTherapyCoding variantPredictive responseScoresCarotid stent extrusion following carotid blowout
Aaronson N, Johnson M, Sasaki C. Carotid stent extrusion following carotid blowout. Auris Nasus Larynx 2015, 42: 176-178. PMID: 25579083, DOI: 10.1016/j.anl.2014.10.016.Peer-Reviewed Original ResearchConceptsCarotid blowoutStent extrusionStent placementCT angiographyCarotid stentsSingle-patient case reportTonsil squamous cell carcinomaEvidence of extravasationSquamous cell carcinomaCarotid stent placementNeck cancer patientsYear old femalePatient case reportUnusual foreign bodyAcute stridorCell carcinomaUpper airwayCancer patientsCase reportPatient prognosisForeign bodyOld femalePatientsStentsAirway
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply